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ABSTRACT
Preeclampsia (PE), the primary pathology of which is endothelial cell (EC) dysfunction, has long-lasting
effects such as cardiovascular disease. Therefore, it was decided to investigate the maternal serum con-
centrations of EC-specific molecule-1 in patients with early-onset preeclampsia (E-PE). This study was
conducted on 33 pregnant women with E-PE and 35 healthy pregnant women matched for gestational
age. EC-specific molecule-1 level was measured using a commercially available enzyme-linked immuno-
sorbent assay kit. The mean EC-specific molecule-1 concentrations were not significantly different
between the groups (651.7 ±632.2 pg/mL vs. 425.9 ±263.0 pg/mL, p¼.056). Among women with E-PE,
the median EC-specific molecule-1 concentration did not differ significantly by disease severity
(p¼.115). EC-specific molecule-1 is not involved in the pathogenesis of E-PE. However, some studies in
the literature report that EC-specific molecule-1 concentrations increased during the diagnosis of PE.
Therefore, well-designed studies with a large sample are needed in cases of E-PE.
IMPACT STATEMENT
 What is already known on this subject? There is an increased risk of cardiovascular disease (CVD)
in early-onset preeclampsia (E-PE) which is linked with endothelial dysfunction. Endothelial cell
(EC)-specific molecule-1 stands out as an important marker in EC dysfunction related conditions
such as preeclampsia.
 What the results of this study add? This study showed that EC-specific molecule-1 is not associ-
ated with the CVDs risk linked with endothelial dysfunction in E-PE. Additionally, there was also no
significant relationship was detected between the severity of E-PE and EC-specific molecule-1
concentrations.
 What the implications are of these findings for clinical practice and/or further research?
Endothelial cell-specific molecule-1 is not involved in the pathogenesis of E-PE. Moreover, advanta-









Hypertensive disorders during pregnancy such as preeclamp-
sia (PE) and eclampsia are serious conditions with significant
maternal and/or foetal morbidity and/or mortality. The preva-
lence of PE is between 2% and 8%. Proteinuria onset after
20 weeks and high blood pressure characterised by endothe-
lial cell (EC) dysfunction are its main characteristics (Purde
et al. 2015; K€oninger et al. 2018). Some risk factors are held
responsible for this; obesity, maternal age of 35 years and
nulliparity (Brosens et al. 2019). The aim of the studies con-
ducted using biophysical markers (e.g. maternal body mass
index (BMI) and mean arterial pressure), placental, inflamma-
tory, endothelial and metabolic biomarkers or a combination
thereof, is to indicate an abnormal response to placentation
and predict PE. However, a test/method that predicts PE or
confirms its diagnosis before its clinical occurrence has not
yet been found. Dividing PE into two types by determining
the cut-off period as 34 weeks is a widely accepted approach
(early/placental and late onset/maternal). Furthermore, it can
also be classified as vascular remodelling/placental invasion
or inflammation/metabolic depending on its underlying
pathophysiology (Eastabrook et al. 2018). Oxidative stress
occurs due to the effect of placental hypoperfusion/hypoxia/
ischemia, which is followed by cellular apoptosis, inflamma-
tion and the delivery of antiangiogenic factors to the mater-
nal circulation. Eventually, numerous factors such as soluble
fms-like tyrosine kinase-1 and placental growth factor
released by the placenta contribute to EC damage and the
development of PE (Herraiz et al. 2018).
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On the other hand, when the placenta was examined in
early-onset preeclampsia (E-PE), it has been observed that
the vessels tend to develop acute atherosis. In brief, the
events that occur during the formation of atherosis are intra-
vascular inflammation, macrophage infiltration, EC dysfunc-
tion and changes in lipid metabolism. Atherosclerosis may
spread to the whole body. It is possible that a lower level of
hypertension in the placental bed may also occur in other
organs (Brosens et al. 2019). In elderly people, the primary
pathology of atherosclerosis is also EC dysfunction (Gimbrone
and Garcıa-Carde~na 2016). In addition, higher concentrations
of serum EC-specific molecule-1 were demonstrated in condi-
tions characterised by the vascular involvement of athero-
sclerosis (Roudnicky et al. 2013).
Endothelial cell-specific molecule-1, which has recently
been named endocan (ESM-1), is a soluble dermatan sulphate
proteoglycan. It is considered a biomarker for EC activation/
dysfunction. It has been shown to be released in cases of cell
adhesion, tumour and inflammation in the human body. In
normal or pathologic processes, inflammatory mediators and
angiogenic growth factors may affect EC-specific molecule-1,
with which they are in a close relationship (Sarrazin et al.
2006; Aparci et al. 2015). Many studies have also demon-
strated the influence of the vascular endothelial growth fac-
tor (VEGF) family, whose relationship with PE has been
shown, with EC-specific molecule-1 (Chang et al. 2015).
Schuitemaker et al. demonstrated through plasma EC-specific
molecule-1 measurements that healthy pregnant women
exhibited a decrease compared with healthy non-pregnant
women, and detected that EC-specific molecule-1 decreased
in healthy pregnant women from the first trimester until the
end of pregnancy (Schuitemaker et al. 2018).
In a study comparing healthy pregnant women and patients
with PE, it was detected that serum EC-specific molecule-1 level
was higher in preeclamptic pregnant women, although there
was no correlation with its severity (Adekola et al. 2015). There
are studies that demonstrate that EC-specific molecule-1 con-
centrations are also in high in late-onset preeclampsia (L-PE). In
addition, preeclamptic women have an increased risk of cardio-
vascular diseases (CVDs) and metabolic disorders in ensuing
years (Powe et al. 2011; Gooding and Johnson 2016). EC-specific
molecule-1, which was demonstrated to be high in CVDs, was
also found to be high in the placenta in PE (Chang et al. 2015).
It may be beneficial to study EC-specific molecule-1 concentra-
tions both in acute phases of E-PE and with respect to the
long-term effects of PE.
The aim of this study was to evaluate EC-specific mol-
ecule-1 concentrations in E-PE and address its relationship
with its severity.
Methods
This observational case-control study was designed at
Cengiz Gokcek Women’s and Children’s Hospital, Gaziantep,
Turkey, in the Department of Obstetrics and Gynecology
between December 2017 and September 2018. The study
protocol was approved by the Ethics Committee for Clinical
Research of the Gaziantep University (reference number:
362, date 06 November 2017). The study was conducted
according to the principles of the Declaration of Helsinki. All
subjects included in the study gave oral and written
informed consent. The study population consisted of 33
women with a singleton pregnancy who were diagnosed as
having E-PE between 26 þ 0 and 33 þ 6 weeks of gestation.
Thirty-five gestational age-matched healthy pregnant
women who delivered at term were included in the study
as the control group. The gestational age was determined
by calculating the days from the last menstrual period and
was supported by ultrasonographic measurements at the
first trimester of gestation.
E-PE was defined as new-onset of hypertension (on two
occasions at least 4 h apart, diastolic and/or systolic blood
pressure of 90 and/or 140 mm Hg) between the 20th and
34th week of pregnancy with a concomitant proteinuria
(300 mg in a 24-h urine or 1 (þ) protein by dipstick test on
two random urine samples). Diastolic and/or systolic blood
pressure up to 110/160 mm Hg was considered mild, and
higher values were considered to be severe (ACOG 2019). In
the E-PE group, neonates assessed as small for gestational
age (SGA) were defined as birth weight <10th percentile for
gestational age with Turkey’s national nomogram as the ref-
erence for foetal growth (Topçu et al. 2014). Maternal BMI
(kg/m2) was measured as the ratio of the weight (kg) to the
square of the height (m).
The exclusion criteria were as follows: (1) pregnant women
with any systemic condition (such as chronic hypertension,
diabetes mellitus, thyroid diseases, liver and kidney diseases),
(2) women with a history of drug use throughout pregnancy,
(3) pregnant women who had fever at the time of first
admission, (4) history of medication for PE treatment at the
time of first admission, (4) pregnancies complicated with pre-
mature membrane rupture or chorioamnionitis, (5) patients
who had foetal congenital abnormalities or genetic syn-
dromes, (6) smoking, (7) multiple gestation and (8) active
labour. Healthy subjects who had a normal pregnancy and
outcomes without any foetal-neonatal complications were
accepted into the control group. Four patients in the control
group and two patients in E-PE group were excluded from
study because they declined to participate. Incomplete feto-
maternal data were seen in one patient in the control group
and one patient in the E-PE group. Two patients in the con-
trol group had low birth weight and SGA at birth. These
patients were also excluded from the study. The remaining
33 pregnant women with E-PE and 35 healthy subjects were
eligible for inclusion in the study (Figure 1).
Every woman in the study population underwent an
obstetric ultrasound examination and a foetal–maternal
assessment was conducted by one of the authors. Obstetric
anamneses were obtained from all subjects. The demo-
graphic data for gestational age, gravidity, parity, maternal
age and BMI were recorded. Maternal venous blood sam-
ples were taken for measurement of EC-specific molecule-1
level after the diagnosis of E-PE in the outpatient clinic.
These samples were quickly centrifuged at 1500g for
10 min, plasma and serum samples were separated, and
serum samples were stored at 80 C until the day of ana-
lysis. All patients with E-PE were hospitalised. A
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betamethasone injection was administered immediately
after hospitalisation. The pregnancy was immediately termi-
nated in emergencies arising from maternal or foetal
causes. Otherwise, blood pressure was measured every four
hours during periods of rest. Hypertension can be con-
firmed within a shorter interval in patients with blood pres-
sure 110 mm Hg diastolic and 160 mm Hg systolic in
order to give timely antihypertensive treatment. Delivery
should be postponed for at least 24–48 hours if maternal/
foetal status permit. A betamethasone injection for lung
maturation (two dosages of 12 mg at 24-h intervals) was
given within the said period. The control group’s samples
were obtained during routine obstetric care examinations
in the third trimester of pregnancy. These pregnant women
were then followed up until delivery.
Serum EC-specific molecule-1 concentrations were meas-
ured using a commercially available enzyme-linked
immunosorbent assay (ELISA) kit specifically produced to
detect human EC-specific molecule-1 with a high sensitivity
and specificity (Elabscience Biotechnology Inc, Houston,
TX). The measurements were undertaken in accordance
with the company’s protocols. The kit uses the sandwich-
ELISA principle. A biotinylated detection antibody specific
for human EC-specific molecule-1 and avidin-horseradish
peroxidase conjugate was used in the measurements.
Spectrophotometry at a wavelength of 450 nm± 2 nm was
used for the detection of optical density, which is propor-
tional to the concentration of human EC-specific molecule-
1. The intra-assay and inter-assay variation coefficients were
6.36% and 6.09%, respectively.
Statistical analysis
Frequency and percentage analyses were used for some vari-
ables during data analysis. In addition, an independent sam-
ples t-test (Student’s t-test) was used for the comparison of
the EC-specific molecule-1 concentrations by the variable
groups formed. The SPSS (IBM SPSS Statistics for Windows,
Version 22.0, IBM Corp., Armonk, NY) statistical program was
used for all statistical calculations.
Results
A week after admission, only one of the patients in the E-PE
group gave birth. The pregnancy of the other patients had to
be terminated either immediately or as soon as the adminis-
tration of betamethasone was completed. The demographic
data and biochemical parameters of the E-PE group were
compared with those of the control group (Table 1). No teen-
age pregnancies were found in the E-PE group when the
maternal ages were examined. There were seven pregnant
women aged 35 years in the advanced maternal age (AMA)
group in the E-PE group, the average EC-specific molecule-1
concentrations of whom were not statistically different from
those who were aged <35 years (p¼ .801). The EC-specific
molecule-1 concentrations of the eight AMA pregnancies in
the control group did not differ from those of women aged
<35 years in control group (p¼ .226). The EC-specific mol-
ecule-1 concentrations of all AMA pregnancies in both
groups did not differ from those of the women aged
<35 years (p¼ .507). In the E-PE group, the EC-specific mol-
ecule-1 concentrations of the women whose gestational age
was <32weeks did not differ from those whose gestational
age was 32weeks (p¼ .250).
No difference was detected between EC-specific molecule-
1 concentrations in the severe (n¼ 24) band mild E-PE (n¼ 9)
groups (p¼ .115). When Pearson’s correlation was applied
between the severity of proteinuria measured with a dipstick
and EC-specific molecule-1 concentrations in the E-PE group,
a statistically insignificantly negative relationship was
detected (r¼0.115, p¼ .523).
No difference was found when the EC-specific molecule-1
concentrations of the women having their first pregnancy (68
women in both groups) and those having their 2nd preg-
nancies were compared (p¼ .635).
As there were few SGA infants in the E-PE group (four
infants), their EC-specific molecule-1 concentrations could not
be compared.
When the EC-specific molecule-1 concentrations of those
with a BMI <30 kg/m2 and 30 kg/m2 were compared, no
difference was observed in all pregnant women (p¼ .084).
When the EC-specific molecule-1 concentrations of those
with a BMI <30 kg/m2 and 30 kg/m2 were compared, no
difference was observed in the E-PE group (p¼ .148). When
the EC-specific molecule-1 concentrations of those with a
BMI <30 kg/m2 and 30 kg/m2 were compared, no differ-
ence was observed in the control group either (p¼ .223).
When the EC-specific molecule-1 concentrations of those in
the E-PE group with high and low uric acid concentrations
were analysed, no difference was detected (p¼ .398).
Figure 1. Flowchart of the pregnant women recruited in the study.
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Discussion
Our hypothesis in this current study was that EC-specific mol-
ecule-1, as an EC dysfunction marker, would be increased in
women with E-PE. In contrast to our hypothesis, we found no
significant difference in maternal EC-specific molecule-1 con-
centrations between the E-PE and healthy pregnancies. There
was also no significant relationship was detected between
the severity of E-PE and EC-specific molecule-1
concentrations.
The placenta is the interface between the mother and the
foetus. The development of the placental villi should be com-
pleted for placental circulation. The course of development
should involve vasculogenesis, angiogenesis, enlargement of
the placental vascular tree, and placental growth, respect-
ively. Initially, the vessels grow from 18 to 20 days post-con-
ception from the ECs. Angiogenesis and placentation
continue to develop, and the constituted vascular casts from
pregnancies complicated by E-PE have demonstrated import-
ant differences in the placental vessels compared with
healthy pregnancies. In addition, in a study where placental
ECs were isolated from term placentae, the ECs obtained
from PE pregnant women were found to be less viable than
those obtained from the control group. ECs have a reduced
proliferation rate and are more susceptible to apoptosis;
these phases precede the patients’ diagnosis. In addition, the
angiogenic imbalance has been shown to drive the progres-
sion of PE. The diagnosis is made based on the clinical symp-
toms when the patient is admitted (Charolidi et al. 2019).
The PE findings obtained when placentas were examined
were ischaemic lesions, shallow placental implantation, decid-
ual arteriopathy and uteroplacental malperfusion. These find-
ings can be observed in E-PE and L-PE. However, more
findings were observed in E-PE. In light of clinical examina-
tions, there is a possibility of severe PE occurrence in E-PE
compared to L-PE (Stanek 2019). Although the onset of the
event dates back to earlier periods, its outcome affects the
future quality of life and wellbeing of the woman and the
infant. Physicians mostly focus on the time when the patient
clinically presented with hypertension. The development of
chronic progression following acute events is not fully under-
stood. CVD risk was detected to be 2–7 times as high, espe-
cially in E-PE except for short-term implications (Hooijschuur
et al. 2019). Tests to be used for detecting and predicting
these progressions are needed. Studies are needed on how
to follow-up patients for the risk of CVD development, the
measures to be taken, and the treatment to be administered
(Stanek 2019). Moreover, the cost of the events both for the
mother and the baby is of concern. The financial burden of
PE may increase to high levels due to its long-lasting effects
(Eddy et al. 2018).
There are many studies in the literature that demonstrate
that EC-specific molecule-1 concentrations increase in cases
of hypertension. Furthermore, patients with hypertension
treated with valsartan and amlodipine were detected to have
significantly lowered EC-specific molecule-1 concentrations.
EC-specific molecule-1 stands out as a new marker in EC dys-
function-related conditions (Balta et al. 2014; Aparci et al.
2015). Patients with PE had a higher VEGF family. Meanwhile,
the VEGF family was shown to increase EC-specific molecule-
1 concentrations. Spreza-Gozdziewicz et al. observed that
there was no difference between E-PE and L-PE in terms of
maternal serum EC-specific molecule-1 concentrations in
healthy pregnant women. In addition, they detected in their
analyses that PE severity and EC-specific molecule-1 concen-
trations were not correlated (Szpera-Gozdziewicz et al. 2020).
Adekola et al. showed higher serum EC-specific molecule-1
concentrations in patients with PE than in the control group,
but subgroup analysis revealed no differences in the severity
of the condition (mild/severe PE) or the gestational age at
diagnosis (E-PE/L-PE) (Adekola et al. 2015). Further, in a study
conducted with only E-PE patients, a comparison with a con-
trol group revealed no difference between maternal serum
EC-specific molecule-1 concentrations (Yuksel et al. 2015).
Table 1. The demographic data and biochemical parameters of the groups.
Variables E-PE (n¼ 33) Control (n¼ 35) t p Value
Age (years) 29.1 ± 6.4 29.2 ± 6.9 –0.030 .976
Body mass index (kg/m2) 31.2 ± 4.9 31.0 ± 7.8 0.111 .912
Gestational age at blood sampling (weeks) 31.1 ± 2.2 30.5 ± 2.0 1.278 .206
Gravidity 2.9 ± 1.7 3.4 ± 2.1 –1.025 .309
Parity 1.4 ± 1.4 1.8 ± 1.6 –0.990 .326
Systolic blood pressure (mm Hg) 172 ± 17 102 ± 10 20.244 <.001
Diastolic blood pressure (mm Hg) 110 ± 11 65 ± 7 18.972 <.001
Spot urine proteinuria by dipstick test 3.1 ± 1.2 0.2 ± 0.4 13.468 <.001
Haemoglobin (g/dL) 12 ± 1.4 11.6 ± 1.1 1.174 .245
Haematocrit (%) 35.9 ± 3.9 34.2 ± 2.5 2.065 .043
Platelets (103/mL) 201 ± 82 243 ± 58 –2.462 .016
White blood cells (mL/mL) 10.6 ± 2.8 10.0 ± 2.6 0.873 .386
Uric acid (mg/dL) 5.7 ± 1.3 3.8 ± 0.7 7.047 <.001
Albumin (g/dL) 2.9 ± 0.8 3.5 ± 0.3 –3.605 .001
Blood urea nitrogen (mg/dL) 10.4 ± 3.8 7.1 ± 2.0 4.477 <.001
Creatinine (mg/dL) 0.67 ± 0.15 0.49 ± 0.11 5.558 <.001
Alanine aminotransferase (IU/L) 24.6 ± 31.3 12.5 ± 9.3 2.197 .032
Aspartate aminotransferase (U/L) 33.5 ± 36.4 16.2 ± 6.9 2.757 .008
Lactic acid dehydrogenase (units/L) 352.6 ± 188.1 205.6 ± 60.0 4.393 <.001
Birth weight (g) 1611 ± 444 3234 ± 342 –16.923 <.001
Endocan level (pg/mL) 651.7 ± 632.2 425.9 ± 263.0 1.942 .056
E-PE: early-onset preeclampsia group; control: control group.
Values are given as mean ± SD.p<.05 indicates statistical significance.
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Hentschke et al. found in their study that EC-specific mol-
ecule-1 concentrations were high in the E-PE group; however,
this study was conducted on maternal plasma (Hentschke
et al. 2018). Chang et al. examined the placentae of patients
with L-PE and detected that the expression of EC-specific
molecule-1 mRNA and protein concentrations had increased
in those patients (Chang et al. 2015). The study by Chew
et al. included both E-PE and L-PE patients and high concen-
trations of EC-specific molecule-1 were also detected in the
placenta. Chew et al. detected that the EC-specific molecule-
1 concentrations were also high in foetal ECs, decidual cells
and maternal ECs in the placenta of pregnant women with
PE (Chew et al. 2019). When Schuitemaker et al. compared
EC-specific molecule-1 in healthy pregnant women in their
study, they found a remarkable increase in EC-specific mol-
ecule-1 concentrations at the time of diagnosis of E-PE and
L-PE. They reported an increase in the EC-specific molecule-1
concentrations at 32weeks in E-PE. They also reported no
increase in the EC-specific molecule-1 concentrations in the
placenta but observed an increase in maternal ECs
(Schuitemaker et al. 2018). In the present study, although a
mild increase in EC-specific molecule-1 concentrations was
observed in E-PE, it was not statistically significant. In this
study, no correlation was detected in the severe E-PE group.
Also in this study, no increase was detected at 32weeks in
the severe E-PE group. The results of the studies in the litera-
ture were inconclusive. The differences in the results of the
studies may be due to the fact that they were performed
without separating the E-PE/L-PE groups or mild/severe
groups. It may also be based on the fact that different inclu-
sion criteria were used in E-PE or different samples (plasma,
serum or placenta) were studied, and that the number of
pregnant women in the studies differed and were
insufficient.
There are publications showing an increased risk of CVDs
with increased BMI, as well as numerous publications report-
ing an increased risk of PE with increased BMI (Kachur et al.
2017). In the present study, patients with obesity were evenly
distributed across the groups. Our results show that EC-spe-
cific molecule-1 is not affected by obesity. In addition, ado-
lescent women who had PE in their first pregnancy were
detected to be at risk for chronic hypertension in subsequent
pregnancies and the later stages of their lives (Sibai et al.
1986; Brosens et al. 2019). In this current study, which did
not include any adolescent pregnancies, and no difference
was found in EC-specific molecule-1 concentrations between
women having their first pregnancy and those having their
2nd pregnancies. The fact that there were no adolescent
pregnancies may have affected this result. PE development is
considered to be a risk factor for metabolic syndrome and
CVDs in AMA pregnancies, particularly with the coexistence
of SGA (Hooijschuur et al. 2019). In this study, EC-specific
molecule-1 concentrations in AMA pregnancies did not differ.
Higher uric acid concentrations have also been suggested as
a predictor of PE, as well as CVDs, cerebrovascular diseases
and unhealthy obesity (Eastabrook et al. 2018). In the present
study, it was observed that there was no difference in EC-
specific molecule-1 concentrations in the patients with nor-
mal and high uric acid concentrations in the E-PE group.
The fact that smoking, which is among the factors that
might affect ECs, was excluded from evaluation is considered
a strength in this study. The major limitation of our study is
that the number of patients with E-PE was quite low. A
causal relationship has not been established between EC-spe-
cific molecule-1 and PE because of the cross-sectional design.
We did not measure angiogenic growth factors (such as
VEGFs and placental growth factor) and antiangiogenic bio-
markers (such as soluble fms-like tyrosine kinase-1). The fact
that it was not possible to measure EC-specific molecule-1
concentrations in the placentae of the patients is another
limitation.
PE is known to develop as a result of endothelial dysfunc-
tion and several molecules/markers have been studied to elu-
cidate the exact pathogenesis of the disease. However, to
date, there have been studies concerning this issue and the
findings were inconclusive. Hence, further investigations with
larger sample sizes are needed in order to elucidate the role
of EC-specific molecule-1 and other endothelial markers in
the etiopathogenesis of PE.
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